L‑type amino acid transporter 1 in enhancing boron neutron capture therapy: Mechanisms, challenges and future directions (Review)

Sun B, Li R, Ji N, Liu H, Wang H, Chen C, Bai L, Su J and Chen J: Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma. Mater Today Bio. 30:1014432025. View Article : Google Scholar : PubMed/NCBI

Sun Y: Boron neutron capture therapy: Moving towards targeted therapy for locally recurrent head and neck squamous cell carcinoma. Mil Med Res. 6:322019.PubMed/NCBI

Takai S, Wanibuchi M, Kawabata S, Takeuchi K, Sakurai Y, Suzuki M, Ono K and Miyatake SI: Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol. 24:90–98. 2022. View Article : Google Scholar :

Sköld K, H-Stenstam B, Diaz AZ, Giusti V, Pellettieri L and Hopewell JW: Boron Neutron Capture Therapy for glioblastoma multiforme: Advantage of prolonged infusion of BPA-f. Acta Neurol Scand. 122:58–62. 2010. View Article : Google Scholar

Wongthai P, Hagiwara K, Miyoshi Y, Wiriyasermkul P, Wei L, Ohgaki R, Kato I, Hamase K, Nagamori S and Kanai Y: Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. Cancer Sci. 106:279–286. 2015. View Article : Google Scholar : PubMed/NCBI

Kankaanranta L, Seppälä T, Koivunoro H, Välimäki P, Beule A, Collan J, Kortesniemi M, Uusi-Simola J, Kotiluoto P, Auterinen I, et al: l-Boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: A phase I study. Int J Radiat Oncol Biol Phys. 80:369–376. 2011. View Article : Google Scholar : PubMed/NCBI

Menéndez PR, Roth BMC, Pereira MD, Casal MR, González SJ, Feld DB, Santa Cruz GA, Kessler J, Longhino J, Blaumann H, et al: BNCT for skin melanoma in extremities: Updated Argentine clinical results. Appl Radiat Isot. 67(7-8 Suppl): S50–S53. 2009. View Article : Google Scholar : PubMed/NCBI

Fukuda H: Boron neutron capture therapy (BNCT) for cutaneous malignant melanoma using 10B-p-Boronophenylalanine (BPA) with special reference to the radiobiological basis and clinical results. Cells. 10:28812021. View Article : Google Scholar :

Suzuki M, Sakurai Y, Hagiwara S, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Kudo M and Ono K: First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol. 37:376–381. 2007. View Article : Google Scholar : PubMed/NCBI

Kawabata S, Hiramatsu R, Kuroiwa T, Ono K and Miyatake SI: Boron neutron capture therapy for recurrent high-grade meningiomas. J Neurosurg. 119:837–844. 2013. View Article : Google Scholar : PubMed/NCBI

Järvinen J, Pulkkinen H, Rautio J and Timonen JM: Amino acid-based boron carriers in boron neutron capture therapy (BNCT). Pharmaceutics. 15:26632023. View Article : Google Scholar : PubMed/NCBI

Raitano A, Martin T, Zhang C, Malinao MC, Capo L, Ikeura M, Carroll R, Quintana JC, Dlamini S, Kulenovic L, et al: Boronotyrosine, a borylated amino acid mimetic with enhanced solubility, tumor boron delivery, and retention for the re-emerging boron neutron capture therapy field. J Med Chem. 66:13809–13820. 2023. View Article : Google Scholar : PubMed/NCBI

Kashihara T, Mori T, Nakaichi T, Nakamura S, Ito K, Kurihara H, Kusumoto M, Itami J, Yoshimoto S and Igaki H: Correlation between L-amino acid transporter 1 expression and 4-borono-2-18F-fluoro-phenylalanine accumulation in humans. Cancer Med. 12:20564–20572. 2023. View Article : Google Scholar : PubMed/NCBI

Li J, Shi Y, Zhang Z, Liu H, Lang L, Liu T, Chen X and Liu Z: A metabolically stable boron-derived tyrosine serves as a theranostic agent for positron emission tomography guided boron neutron capture therapy. Bioconjug Chem. 30:2870–2878. 2019. View Article : Google Scholar : PubMed/NCBI

Wittig A, Sauerwein WA and Coderre JA: Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 153:173–180. 2000. View Article : Google Scholar : PubMed/NCBI

Zhang L, Sui C, Yang W and Luo Q: Amino acid transporters: Emerging roles in drug delivery for tumor-targeting therapy. Asian J Pharm Sci. 15:192–206. 2020.PubMed/NCBI

Detta A and Cruickshank GS: l-amino acid transporter-1 and boronophenylalanine-based boron neutron capture therapy of human brain tumors. Cancer Res. 69:2126–2132. 2009. View Article : Google Scholar : PubMed/NCBI

Cappoli N, Jenkinson MD, Dello Russo C and Dickens D: LAT1, a novel pharmacological target for the treatment of glioblastoma. Biochem Pharmacol. 201:1151032022. View Article : Google Scholar : PubMed/NCBI

Miyabe J, Ohgaki R, Saito K, Wei L, Quan L, Jin C, Liu X, Okuda S, Nagamori S, Ohki H, et al: Boron delivery for boron neutron capture therapy targeting a cancer-upregulated oligopeptide transporter. J Pharmacol Sci. 139:215–222. 2019. View Article : Google Scholar : PubMed/NCBI

Timonen JM: Amino acids in boron neutron capture therapy-prospects for precise treatment of malignant brain tumors. Gen Chem. 6:1900242020. View Article : Google Scholar

Chiu YL, Fu WY, Huang WY, Hsu FT, Chen HW, Wang TW and Keng PY: Enhancing cancer therapy: Boron-rich polyboronate ester micelles for synergistic boron neutron capture therapy and PD-1/PD-L1 checkpoint blockade. Biomater Res. 28:00402024. View Article : Google Scholar : PubMed/NCBI

Zhu X, Zheng W, Wang X, Li Z, Shen X, Chen Q, Lu Y, Chen K, Ai S, Zhu Y, et al: Enhanced photodynamic therapy synergizing with inhibition of tumor neutrophil ferroptosis boosts Anti-PD-1 therapy of gastric cancer. Adv Sci (Weinh). 11:e23078702024. View Article : Google Scholar : PubMed/NCBI

Shi Y, Guo Z, Fu Q, Shen X, Zhang Z, Sun W, Wang J, Sun J, Zhang Z, Liu T, et al: Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. Nat Commun. 14:18842023. View Article : Google Scholar : PubMed/NCBI

Li J, Sun Q, Lu C, Xiao H, Guo Z, Duan D, Zhang Z, Liu T and Liu Z: Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 13:21432022. View Article : Google Scholar : PubMed/NCBI

Narayanasamy S, Thirumamagal BT, Johnsamuel J, Byun Y, Al-Madhoun AS, Usova E, Cosquer GY, Yan J, Bandyopadhyaya AK, Tiwari R, et al: Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. Bioorg Med Chem. 14:6886–6899. 2006. View Article : Google Scholar : PubMed/NCBI

Skwierawska D, López-Valverde JA, Balcerzyk M and Leal A: Clinical viability of boron neutron capture therapy for personalized radiation treatment. Cancers (Basel). 14:28652022. View Article : Google Scholar : PubMed/NCBI

Henriksson R, Capala J, Michanek A, Lindahl SA, Salford LG, Franzén L, Blomquist E, Westlin JE and Bergenheim AT; Swedish Brain Tumour Study Group: Boron neutron capture therapy (BNCT) for glioblastoma multiforme: A phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol. 88:183–191. 2006. View Article : Google Scholar

Suzuki M: Boron neutron capture therapy (BNCT): A unique role in radiotherapy with a view to entering the accelerator-based BNCT era. Int J Clin Oncol. 25:43–50. 2020. View Article : Google Scholar

Dymova MA, Taskaev SY, Richter VA and Kuligina EV: Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond). 40:406–421. 2020. View Article : Google Scholar : PubMed/NCBI

Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, Kirihata M, Nakazawa M and Yura Y: Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot. 61:1069–1073. 2004. View Article : Google Scholar : PubMed/NCBI

Ohnishi K, Misawa M, Sikano N, Nakai K and Suzuki M: Enhancement of cancer cell-killing effects of boron neutron capture therapy by manipulating the expression of L-type amino acid transporter 1. Radiat Res. 196:17–22. 2021. View Article : Google Scholar : PubMed/NCBI

Javid M, Brownell GL and Sweet WH: The possible use of neutron-capturing isotopes such as boron 10 in the treatment of neoplasms. II. Computation of the radiation energies and estimates of effects in normal and neoplastic brain. J Clin Invest. 31:604–610. 1952. View Article : Google Scholar : PubMed/NCBI

Soloway AH, Hatanaka H and Davis MA: Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem. 10:714–717. 1967. View Article : Google Scholar : PubMed/NCBI

Hawthorne MF: The role of chemistry in the development of boron neutron capture therapy of cancer. Angewandte Chemie International Edition in English. 32:950–984. 1993. View Article : Google Scholar

Hatanaka H and Nakagawa Y: Clinical-results of long-surviving brain-tumor patients who underwent boron neutron-capture therapy. Int J Radiat Oncol Biol Phys. 28:1061–1066. 1994. View Article : Google Scholar : PubMed/NCBI

Barth RF, Gupta N and Kawabata S: Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: An update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun (Lond). 44:893–909. 2024. View Article : Google Scholar : PubMed/NCBI

Matsumura A, Asano T, Hirose K, Igaki H, Kawabata S and Kumada H: Initiatives toward clinical boron neutron capture therapy in Japan. Cancer Biother Radiopharm. 38:201–207. 2023.

Barth RF, Vicente MG, Harling OK, Kiger WS III, Riley KJ, Binns PJ, Wagner FM, Suzuki M, Aihara T, Kato I and Kawabata S: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 7:1462012. View Article : Google Scholar : PubMed/NCBI

Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Välimäki P, et al: Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: Final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 82(1): e67–e75. 2012. View Article : Google Scholar

Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, et al: Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot. 67(7-8 Suppl): S37–S42. 2009. View Article : Google Scholar : PubMed/NCBI

Watabe T, Ose N, Naka S, Fukui E, Kimura T, Kanou T, Funaki S, Sasaki H, Kamiya T, Kurimoto K, et al: Evaluation of LAT1 expression in patients with lung cancer and mediastinal tumors: 18: F-FBPA PET study with immunohistological comparison. Clin Nucl Med. 48:853–860. 2023. View Article : Google Scholar : PubMed/NCBI

Watanabe T, Sanada Y, Hattori Y and Suzuki M: Correlation between the expression of LAT1 in cancer cells and the potential efficacy of boron neutron capture therapy. J Radiat Res. 64:91–98. 2023. View Article : Google Scholar :

Zhang C, Xu J, Xue S and Ye J: Prognostic value of L-type amino acid transporter 1 (LAT1) in various cancers: A meta-analysis. Mol Diagn Ther. 24:523–536. 2020. View Article : Google Scholar : PubMed/NCBI

Chen W, Mehta SC and Lu DR: Selective boron drug delivery to brain tumors for boron neutron capture therapy. Adv Drug Deliv Rev. 26:231–247. 1997. View Article : Google Scholar : PubMed/NCBI

Barth RF, Mi P and Yang W: Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 38:352018.PubMed/NCBI

Hu K, Yang Z, Zhang L, Xie L, Wang L, Xu H, Josephson L, Liang SH and Zhang MR: Boron agents for neutron capture therapy. Coord Chem Rev. 405:2131392020. View Article : Google Scholar

Häfliger P and Charles RP: The L-type amino acid transporter LAT1-An emerging target in cancer. Int J Mol Sci. 20:24282019. View Article : Google Scholar : PubMed/NCBI

Yan R, Zhao X, Lei J and Zhou Q: Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex. Nature. 568:127–130. 2019. View Article : Google Scholar : PubMed/NCBI

Kanai Y: Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics. Pharmacol Ther. 230:1079642022. View Article : Google Scholar

Puris E, Gynther M, Auriola S and Huttunen KM: L-Type amino acid transporter 1 as a target for drug delivery. Pharm Res. 37:882020. View Article : Google Scholar : PubMed/NCBI

Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, et al: Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI

Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R, et al: Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc. Nat Struct Mol Biol. 26:510–517. 2019. View Article : Google Scholar : PubMed/NCBI

Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998. View Article : Google Scholar : PubMed/NCBI

Yan R, Li Y, Müller J, Zhang Y, Singer S, Xia L, Zhong X, Gertsch J, Altmann KH and Zhou Q: Mechanism of substrate transport and inhibition of the human LAT1-4F2hc amino acid transporter. Cell Discov. 7:162021. View Article : Google Scholar : PubMed/NCBI

Lee Y, Jin C, Ohgaki R, Xu M, Ogasawara S, Warshamanage R, Yamashita K, Murshudov G, Nureki O, Murata T and Kanai Y: Structural basis of anticancer drug recognition and amino acid transport by LAT1. Nat Commun. 16:16352025. View Article : Google Scholar : PubMed/NCBI

Singh N and Ecker GF: Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1. Int J Mol Sci. 19:12782018. View Article : Google Scholar : PubMed/NCBI

Yan R, Zhou J, Li Y, Lei J and Zhou Q: Structural insight into the substrate recognition and transport mechanism of the human LAT2-4F2hc complex. Cell Discov. 6:822020. View Article : Google Scholar : PubMed/NCBI

Wang Y, Qin L, Chen W, Chen Q, Sun J and Wang G: Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1. Eur J Med Chem. 226:1138062021. View Article : Google Scholar : PubMed/NCBI

Verrey F: System L: Heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch. 445:529–533. 2003. View Article : Google Scholar : PubMed/NCBI

Chen S, Jin C, Ohgaki R, Xu M, Okanishi H and Kanai Y: Structure-activity characteristics of phenylalanine analogs selectively transported by L-type amino acid transporter 1 (LAT1). Sci Rep. 14:46512024. View Article : Google Scholar : PubMed/NCBI

Ahmed HS: The multifaceted role of L-type amino acid transporter 1 at the blood-brain barrier: Structural implications and therapeutic potential. Mol Neurobiol. 62:3813–3832. 2025. View Article : Google Scholar

Hayashi K and Anzai N: Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment. World J Gastrointest Oncol. 9:21–29. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao Y, Wang L and Pan J: The role of L-type amino acid transporter 1 in human tumors. Intractable Rare Dis Res. 4:165–169. 2015. View Article : Google Scholar : PubMed/NCBI

Häfliger P, Graff J, Rubin M, Stooss A, Dettmer MS, Altmann KH, Gertsch J and Charles RP: The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. J Exp Clin Cancer Res. 37:2342018. View Article : Google Scholar : PubMed/NCBI

Brunocilla C, Console L, Rovella F and Indiveri C: Insights into the transport cycle of LAT1 and interaction with the inhibitor JPH203. Int J Mol Sci. 24:40422023. View Article : Google Scholar : PubMed/NCBI

Papaspyrou M, Feinendegen LE and Müller-Gärtner HW: Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells. Cancer Res. 54:6311–6314. 1994.PubMed/NCBI

Capuani S, Gili T, Bozzali M, Russo S, Porcari P, Cametti C, D'Amore E, Colasanti M, Venturini G, Maraviglia B, et al: L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: A new strategy to improve BNCT efficacy. Int J Radiat Oncol Biol Phys. 72:562–567. 2008. View Article : Google Scholar : PubMed/NCBI

Yoshimoto M, Kurihara H, Honda N, Kawai K, Ohe K, Fujii H, Itami J and Arai Y: Predominant contribution of L-type amino acid transporter to 4-borono-2-18F-fluoro-phenylalanine uptake in human glioblastoma cells. Nucl Med Biol. 40:625–629. 2013. View Article : Google Scholar : PubMed/NCBI

Wingelhofer B, Kreis K, Mairinger S, Muchitsch V, Stanek J, Wanek T, Langer O and Kuntner C: Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. Appl Radiat Isot. 118:67–72. 2016. View Article : Google Scholar : PubMed/NCBI

Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW and Endou H: Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol. 61:729–737. 2002. View Article : Google Scholar : PubMed/NCBI

Xu H, Liu J, Li R, Lin J, Gui L, Wang Y, Jin Z, Xia W, Liu Y, Cheng S, et al: Novel promising boron agents for boron neutron capture therapy: Current status and outlook on the future. Coord Chem Rev. 511:2157952024. View Article : Google Scholar

Yang JU, Kim S, Lee KC, Lee YJ, Kim JY and Park JA: Development of brain-tumor-targeted benzothiazole-based boron complex for boron neutron capture therapy. ACS Med Chem Lett. 13:1615–1620. 2022. View Article : Google Scholar : PubMed/NCBI

Dai L, Wang T, Zhou S, Pan L, Lu Y, Yang T, Wang W and Qian Z: Boronophenylalanine-containing polydopamine nanoparticles for enhanced combined boron neutron capture therapy and photothermal therapy for melanoma treatment. Adv Funct Mater. 34:24028932024. View Article : Google Scholar

Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, et al: LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res. 3:468–478. 2011.PubMed/NCBI

Lu J, Li P, Yang Y, Wang L, Zhang Y, Zhu JY, Zhu XR and Chen MB: Prognostic value of LAT-1 status in solid cancer: A systematic review and meta-analysis. PLoS One. 15:e02336292020. View Article : Google Scholar : PubMed/NCBI

Wang Q and Holst J: L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 5:1281–1294. 2015.PubMed/NCBI

Cai L, Kirchleitner SV, Zhao D, Li M, Tonn JC, Glass R and Kälin RE: Glioblastoma exhibits inter-individual heterogeneity of TSPO and LAT1 expression in neoplastic and parenchymal cells. Int J Mol Sci. 21:6122020. View Article : Google Scholar : PubMed/NCBI

Barth RF, Zhang Z and Liu T: A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun (Lond). 38:362018.PubMed/NCBI

Wang LW, Liu YH, Chou FI and Jiang SH: Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun (Lond). 38:372018.PubMed/NCBI

Kondo N, Barth RF, Miyatake SI, Kawabata S, Suzuki M, Ono K and Lehman NL: Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1R132H mutation-negative glioblastoma. J Neurooncol. 133:107–118. 2017. View Article : Google Scholar : PubMed/NCBI

Zhao X, Sakamoto S, Saito S, Pae S, Yamada Y, Kanaoka S, Wei J, Goto Y, Sazuka T, Imamura Y, et al: The regulation and function of the amino acid transporters LAT1, ASCT2, xCT in urological cancers. Receptors. 3:474–493. 2024. View Article : Google Scholar

Zhang J, Xu Y, Li D, Fu L, Zhang X, Bao Y and Zheng L: Review of the correlation of LAT1 with diseases: mechanism and treatment. Front Chem. 8:5648092020. View Article : Google Scholar : PubMed/NCBI

Sanada Y, Takata T, Tanaka H, Sakurai Y, Watanabe T, Suzuki M and Masunaga S: HIF-1α affects sensitivity of murine squamous cell carcinoma to boron neutron capture therapy with BPA. Int J Radiat Biol. 97:1441–1449. 2021. View Article : Google Scholar

Hayashi K, Jutabha P, Endou H and Anzai N: c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells. Oncol Rep. 28:862–866. 2012. View Article : Google Scholar : PubMed/NCBI

Bhutia YD, Babu E, Ramachandran S and Ganapathy V: Amino acid transporters in cancer and their relevance to 'glutamine addiction': Novel targets for the design of a new class of anticancer drugs. Cancer Res. 75:1782–1788. 2015. View Article : Google Scholar : PubMed/NCBI

Tani T, Fujita T, Misawa M, Tojo N, Shikano N, Suzuki M and Ohnishi K: Advanced boron neutron capture therapy targeting cancer stem cells by selective induction of LAT1 overexpression. Radiat Res. 200:21–31. 2023.PubMed/NCBI

Medina MA, Sánchez-Jiménez F, Márquez J, Rodríguez Quesada A and de Castro Núñez I: Relevance of glutamine metabolism to tumor cell growth. Mol Cell Biochem. 113:1–15. 1992. View Article : Google Scholar : PubMed/NCBI

Fuchs BC and Bode BP: Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol. 15:254–266. 2005. View Article : Google Scholar : PubMed/NCBI

Yoon SJ, Lee CB, Chae SU, Jo SJ and Bae SK: The comprehensive 'Omics' Approach from metabolomics to advanced omics for development of immune checkpoint inhibitors: Potential strategies for next generation of cancer immunotherapy. Int J Mol Sci. 22:69322021. View Article : Google Scholar

Jutabha P, Ouchi M, Otani N and Anzai N: Transport of 4-Boronophenylalanine, a BNCT Delivery Agent, by L-Type Amino Acid Transporters 1 and 2. FASEB J. 29:785.32015. View Article : Google Scholar

Nozaki S, Nakatani Y, Mawatari A, Shibata N, Hume WE, Hayashinaka E, Wada Y, Doi H and Watanabe Y: 18F-FIMP: a LAT1-specific PET probe for discrimination between tumor tissue and inflammation. Sci Rep. 9:157182019. View Article : Google Scholar :

Heikkinen S, Savolainen S and Melkko P: In vitro studies on stability of L-p-boronophenylalanine-fructose Complex (BPA-F). J Radiat Res. 52:360–364. 2011. View Article : Google Scholar : PubMed/NCBI

Shull BK, Spielvogel DE, Head G, Gopalaswamy R, Sankar S and Devito K: Studies on the structure of the complex of the boron neutron capture therapy drug, L-p-boronophenylalanine, with fructose and related carbohydrates: Chemical and 13C NMR Evidence for the b-D-Fructofuranose 2,3,6-(p-phenylalanylorthoboronate) Structure. J Pharm Sci. 89:215–222. 2000. View Article : Google Scholar : PubMed/NCBI

Yoshino K, Yabe T, Hattori T, Saito K, Ishikawa A and Ohki H: (10)B-NMR determination of (10)B-BPA, 10B-BPA-fructose complex and total 10B in blood for BNCT. Appl Radiat Isot. 88:74–77. 2014. View Article : Google Scholar : PubMed/NCBI

Monti Hughes A and Hu N: Optimizing boron neutron capture therapy (BNCT) to treat cancer: An updated review on the latest developments on boron compounds and strategies. Cancers (Basel). 15:40912023. View Article : Google Scholar : PubMed/NCBI

Danzi F, Pacchiana R, Mafficini A, Scupoli MT, Scarpa A, Donadelli M and Fiore A: To metabolomics and beyond: A technological portfolio to investigate cancer metabolism. Sig Transduct Target Ther. 8:1372023. View Article : Google Scholar

Cai Z, Poulos RC, Liu J and Zhong Q: Machine learning for multi-omics data integration in cancer. iScience. 25:1037982022. View Article : Google Scholar : PubMed/NCBI

Babar Q, Saeed A, Tabish TA, Pricl S, Townley H and Thorat N: Novel epigenetic therapeutic strategies and targets in cancer. Biochim Biophys Acta Mol Basis Dis. 1868:1665522022. View Article : Google Scholar : PubMed/NCBI

Kondo N, Hirano F and Temma T: Evaluation of 3-Borono-l-Phenylalanine as a water-soluble boron neutron capture therapy agent. Pharmaceutics. 14:11062022. View Article : Google Scholar : PubMed/NCBI

Augustyn E, Finke K, Zur AA, Hansen L, Heeren N, Chien HC, Lin L, Giacomini KM, Colas C, Schlessinger A and Thomas AA: LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs. Bioorg Med Chem Lett. 26:2616–2621. 2016. View Article : Google Scholar : PubMed/NCBI

Scalise M, Scanga R, Console L, Galluccio M, Pochini L and Indiveri C: Chemical approaches for studying the biology and pharmacology of membrane transporters: The histidine/large amino acid transporter SLC7A5 as a benchmark. Molecules. 26:65622021. View Article : Google Scholar : PubMed/NCBI

Geier EG, Schlessinger A, Fan H, Gable JE, Irwin JJ, Sali A and Giacomini KM: Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1. Proc Natl Acad Sci USA. 110:5480–5485. 2013. View Article : Google Scholar : PubMed/NCBI

Bhutia YD, Babu E, Prasad PD and Ganapathy V: The amino acid transporter SLC6A14 in cancer and its potential use in chemotherapy. Asian J Pharm Sci. 9:293–303. 2014.

Wang LW, Chen YW, Ho CY, Hsueh Liu YW, Chou FI, Liu YH, Liu HM, Peir JJ, Jiang SH, Chang CW, et al: Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: A prospective phase I/II trial. Int J Radiat Oncol Biol Phys. 95:396–403. 2016. View Article : Google Scholar : PubMed/NCBI

Kawabata S, Suzuki M, Hirose K, Tanaka H, Kato T, Goto H, Narita Y and Miyatake SI: Accelerator-based BNCT for patients with recurrent glioblastoma: A multicenter phase II study. Neurooncol Adv. 3:vdab0672021.PubMed/NCBI

Dann SG, Ryskin M, Barsotti AM, Golas J, Shi C, Miranda M, Hosselet C, Lemon L, Lucas J, Karnoub M, et al: Reciprocal regulation of amino acid import and epigenetic state through Lat1 and EZH2. EMBO J. 34:1773–1785. 2015. View Article : Google Scholar : PubMed/NCBI

Yu LY, Hsu CH, Li CY, Hong SY, Chen CR and Chen CS: Evaluating the biological effectiveness of boron neutron capture therapy by using microfluidics-based pancreatic tumor spheroids. Analyst. 148:3045–3056. 2023. View Article : Google Scholar : PubMed/NCBI

Cormerais Y, Pagnuzzi-Boncompagni M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe MF, Pagès G, Pouysségur J and Picco V: Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med. 23:2711–2718. 2019. View Article : Google Scholar : PubMed/NCBI

Konarita K, Kanamori K, Suzuki M, Tokura D, Tanaka S, Honda Y, Nishiyama N and Nomoto T: Poly(vinyl alcohol) potentiating an inert d-amino acid-based drug for boron neutron capture therapy. J Control Release. 377:385–396. 2025. View Article : Google Scholar

Altan B, Kaira K, Watanabe A, Kubo N, Bao P, Dolgormaa G, Bilguun EO, Araki K, Kanai Y, Yokobori T, et al: Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 81:141–153. 2018. View Article : Google Scholar

Sato M, Harada-Shoji N, Toyohara T, Soga T, Itoh M, Miyashita M, Tada H, Amari M, Anzai N, Furumoto S, et al: L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Sci Rep. 11:5892021. View Article : Google Scholar : PubMed/NCBI

Shindo H, Harada-Shoji N, Ebata A, Sato M, Soga T, Miyashita M, Tada H, Kawai M, Kosaka S, Onuki K, et al: Targeting amino acid metabolic reprogramming via L-type amino acid transporter 1 (LAT1) for endocrine-resistant breast cancer. Cancers (Basel). 13:43752021. View Article : Google Scholar : PubMed/NCBI

Jing X, Yang F, Shao C, Wei K, Xie M, Shen H and Shu Y: Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 18:1572019. View Article : Google Scholar : PubMed/NCBI

Muhammad N, Lee HM and Kim J: Oncology therapeutics targeting the metabolism of amino acids. Cells. 9:19042020. View Article : Google Scholar : PubMed/NCBI

Nwosu ZC, Song MG, di Magliano MP, Lyssiotis CA and Kim SE: Nutrient transporters: Connecting cancer metabolism to therapeutic opportunities. Oncogene. 42:711–724. 2023. View Article : Google Scholar : PubMed/NCBI

Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N, Mizuta R, Kondo N, Takata T, Kitamatsu M, et al: Overcoming immunotherapy resistance and inducing abscopal effects with boron neutron immunotherapy (B-NIT). Cancer Sci. 115:3231–3247. 2024. View Article : Google Scholar : PubMed/NCBI

Chen J, Dai Q, Yang Q, Bao X, Zhou Y, Zhong H, Wu L, Wang T, Zhang Z, Lu Y, et al: Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma. J Nanobiotechnol. 20:1022022. View Article : Google Scholar

Barth RF, Wu G, Yang W, Binns PJ, Riley KJ, Patel H, Coderre JA, Tjarks W, Bandyopadhyaya AK, Thirumamagal BT, et al: Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl Radiat Isot. 61:899–903. 2004. View Article : Google Scholar : PubMed/NCBI

Kim SY, Ong Q, Liao Y, Ding Z, Tan AQL, Lim LTR, Tan HM, Lim SL, Lee QY and Han W: Genetic ablation of LAT1 inhibits growth of liver cancer cells and downregulates mTORC1 signaling. Int J Mol Sci. 24:91712023. View Article : Google Scholar : PubMed/NCBI

Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, et al: L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. Cancer Sci. 115:937–953. 2024. View Article : Google Scholar : PubMed/NCBI

Kandasamy P, Gyimesi G, Kanai Y and Hediger MA: Amino acid transporters revisited: New views in health and disease. Trends Biochem Sci. 43:752–789. 2018. View Article : Google Scholar : PubMed/NCBI

Ohno H, Nakatsu Y, Sakoda H, Kushiyama A, Ono H, Fujishiro M, Otani Y, Okubo H, Yoneda M, Fukushima T, et al: 4F2hc stabilizes GLUT1 protein and increases glucose transport activity. Am J Physiol Cell Physiol. 300:C1047–C1054. 2011. View Article : Google Scholar : PubMed/NCBI

Milkereit R, Persaud A, Vanoaica L, Guetg A, Verrey F and Rotin D: LAPTM4b recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat Commun. 6:72502015. View Article : Google Scholar : PubMed/NCBI

Bay C, Bajraktari-Sylejmani G, Haefeli WE, Burhenne J, Weiss J and Sauter M: Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC3A2) in human brain capillary endothelial cells with rapid UPLC-MS/MS quantification of intracellular isotopically labelled L-Leucine. Int J Mol Sci. 23:36372022. View Article : Google Scholar

Hirano F, Kondo N, Murata Y, Sudani A and Temma T: Assessing the effectiveness of fluorinated and α-methylated 3-boronophenylalanine for improved tumor-specific boron delivery in boron neutron capture therapy. Bioorg Chem. 142:1069402024. View Article : Google Scholar

Morrison K: Development of novel LAT1 targeting small molecules for boron neutron capture therapy (BNCT) and potential application for treating glioblastoma. Neuro Oncol. 24(Suppl 4): iv52022. View Article : Google Scholar :

Fujimoto T, Teraishi F, Kanehira N, Tajima T, Sakurai Y, Kondo N, Yamagami M, Kuwada A, Morihara A, Kitamatsu M, et al: BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug. Biomaterials. 309:1226052024. View Article : Google Scholar : PubMed/NCBI

Li R, Zhang J, Guo J, Xu Y, Duan K, Zheng J, Wan H, Yuan Z and Chen H: Application of nitroimidazole-carbobane-modified phenylalanine derivatives as dual-target boron carriers in boron neutron capture therapy. Mol Pharm. 17:202–211. 2020. View Article : Google Scholar

Rautio J, Gynther M and Laine K: LAT1-mediated prodrug uptake: A way to breach the blood-brain barrier. Ther Deliv. 4:281–284. 2013. View Article : Google Scholar : PubMed/NCBI

Harada T, Hirose K, Wada Y, Sato M, Ichise K, Aoki M, Kato T, Takeda K and Takai Y: YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells. J Radiat Res. 61:524–534. 2020. View Article : Google Scholar : PubMed/NCBI

Kim A, Suzuki M, Matsumoto Y, Fukumitsu N and Nagasaki Y: Non-isotope enriched phenylboronic acid-decorated dual-functional nano-assembles for an actively targeting BNCT drug. Biomaterials. 268:1205512021. View Article : Google Scholar

Chen J, Yang Q, Liu M, Lin M, Wang T, Zhang Z, Zhong X, Guo N, Lu Y, Xu J, et al: Remarkable boron delivery of iRGD-modified polymeric nanoparticles for boron neutron capture therapy. Int J Nanomedicine. 14:8161–8177. 2019. View Article : Google Scholar : PubMed/NCBI

Dai Y, Xu C, Sun X and Chen X: Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. Chem Soc Rev. 46:3830–3852. 2017. View Article : Google Scholar : PubMed/NCBI

Wang Y, Reina G, Kang HG, Chen X, Zou Y, Ishikawa Y, Suzuki M and Komatsu N: Polyglycerol functionalized 10B enriched boron carbide nanoparticle as an effective bimodal anticancer nanosensitizer for boron neutron capture and photothermal therapies. Small. 18:22040442022. View Article : Google Scholar

Bao X, Wu J, Xie Y, Kim S, Michelhaugh S, Jiang J, Mittal S, Sanai N and Li J: Protein expression and functional relevance of efflux and uptake drug transporters at the blood-brain barrier of human brain and glioblastoma. Clin Pharmacol Ther. 107:1116–1127. 2020. View Article : Google Scholar

Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y and Endou H: L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer. 119:484–492. 2006. View Article : Google Scholar : PubMed/NCBI

Kawasaki Y, Suzuki H, Miura M, Hatakeyama H, Suzuki S, Yamada T, Suzuki M, Ito A and Omori Y: LAT1 is associated with poor prognosis and radioresistance in head and neck squamous cell carcinoma. Oncol Lett. 25:1712023. View Article : Google Scholar : PubMed/NCBI

Yoon JH, Kim IJ, Kim H, Kim HJ, Jeong MJ, Ahn SG, Kim SA, Lee CH, Choi BK, Kim JK, et al: Amino acid transport system L is differently expressed in human normal oral keratinocytes and human oral cancer cells. Cancer Lett. 222:237–245. 2005. View Article : Google Scholar : PubMed/NCBI

Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi N, et al: Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer. 110:2506–2513. 2014. View Article : Google Scholar : PubMed/NCBI

Fukumoto S, Hanazono K, Fu DR, Endo Y, Kadosawa T, Iwano H and Uchide T: A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): A pilot study in a canine model. Biochem Biophys Res Commun. 439:103–108. 2013. View Article : Google Scholar : PubMed/NCBI

Hiratsuka J, Kamitani N, Tanaka R, Tokiya R, Yoden E, Sakurai Y and Suzuki M: Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J Radiat Res. 61:945–951. 2020. View Article : Google Scholar : PubMed/NCBI

Shimizu A, Kaira K, Kato M, Yasuda M, Takahashi A, Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Oyama T, et al: Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. Melanoma Res. 25:399–405. 2015. View Article : Google Scholar : PubMed/NCBI

Oldan JD, Giglio BC, Smith E, Zhao W, Bouchard DM, Ivanovic M, Lee YZ, Collichio FA, Meyers MO, Wallack DE, et al: Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizuma b in stage III/IV melanoma. Oncoimmunology. 12:22047532023. View Article : Google Scholar

Farías RO, Bortolussi S, Menéndez PR and González SJ: Exploring boron neutron capture therapy for non-small cell lung cancer. Phys Med. 30:888–897. 2014. View Article : Google Scholar : PubMed/NCBI

Bodoor K, Almomani R, Alqudah M, Haddad Y and Samouri W: LAT1 (SLC7A5) overexpression in negative her2 group of breast cancer: A potential therapy target. Asian Pac J Cancer Prev. 21:1453–1458. 2020. View Article : Google Scholar : PubMed/NCBI

Zhou Z, Zhu T, Zheng W, Zou Z, Shan Q, Chen Q, Wang G and Wang Y: LAT1 transporter as a target for breast cancer diagnosis and therapy. Eur J Med Chem. 283:1170642025. View Article : Google Scholar

Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, et al: Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma. Sci Rep. 9:167762019. View Article : Google Scholar : PubMed/NCBI

Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, Kanai Y and Ichikawa T: Up-Regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells. J Urol. 195:1588–1597. 2016. View Article : Google Scholar

Takahara K, Inamoto T, Minami K, Yoshikawa Y, Takai T, Ibuki N, Hirano H, Nomi H, Kawabata S, Kiyama S, et al: The anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft model. PLoS One. 10:e01369812015. View Article : Google Scholar : PubMed/NCBI

Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H and Okayasu I: L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 59:7–18. 2009. View Article : Google Scholar : PubMed/NCBI

Kaira K, Sunose Y, Arakawa K, Ogawa T, Sunaga N, Shimizu K, Tominaga H, Oriuchi N, Itoh H, Nagamori S, et al: Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer. 107:632–638. 2012. View Article : Google Scholar : PubMed/NCBI